The Institute for Clinical and Economic Review (ICER) on Wednesday posted a Draft Scoping Document on chimeric antigen receptor t-cell (CAR-T) therapies.
According to a press release issued by ICER, the institute will accept public comments until a 5 p.m. EST Aug. 29 deadline.
ICER says it will focus on clinical effectiveness and value research of CAR-T therapies during a California Technology Assessment Forum (CTAF) meeting in March.
“The Draft Scoping Document was developed with input from key stakeholders, including patients and patient advocacy groups, who provided important insights into the context of treatment decisions,” ICER says in a statement. “Of note, patients expressed hope that CAR-T therapy would offer improved survival and better quality of life compared to other treatments they had tried.”
A revised scoping document will be published in September after the public comment deadline passes.
Click here to read the full press release on ICER’s website.
